AME Logo
FV

François Venter

MD, FCP, PhD

Ezintsha, University of the Witwatersrand, South Africa

Biography

Professor WD Francois Venter, MD, FCP, PhD is Executive Director of Wits Ezintsha at the University of the Witwatersrand, Johannesburg, where he received most of his training. His work involves health systems research and clinical trials, most recently involving the antiretrovirals dolutegravir, tenofovir alafenamide, cabotegravir, and doravirine. He leads multiple antiretroviral treatment optimisation studies and is currently working on new access programmes through private pharmacies within South Africa, patient linkage-to-care interventions, self-testing projects, as well as most recently on new large-scale primary care delivery platforms addressing hypertension, diabetes, obesity, hyperlipidaemia and HIV. He has led large PEPFAR-funded HIV programmes in South Africa, focusing on men, women, children, young people, truckers, sex workers, and LGBTI communities. For over 20 years he has been an advisor to bodies such as the South African government, UNAIDS, and WHO, contributing to international, regional, and national HIV guidelines, and recently served as a member of the Ministerial Advisory Committee for COVID-19. He has an active interest in medical ethics and has been involved in several HIV-related human rights cases within the southern African region. He supervises Masters and PhD students and has over 280 publications, including first-author articles in major journals.

RELATED COURSES

CME Series | Long-Acting Anti-Infectives
HIV
COVID-19
RSV
Tuberculosis
Viral Hepatitis and Liver Disease
60 min
Richard Elion, Natella Rakhmanina, François Venter

CME Series | Long-Acting Anti-Infectives

This module focuses on the evolving landscape of long-acting anti-infective therapies, emphasizing recent advances in HIV prevention and treatment. Participants will explore current approved drugs and promising therapies in development, with a special focus on pediatric and adolescent populations. The module also addresses the challenges and opportunities for implementing long-acting antiretrovirals in resource-limited settings.

What Will Set You Apart?

By completing this module, you will:

  • Understand current and emerging long-acting drugs and therapies for HIV prevention
  • Evaluate the progress and challenges in developing long-acting anti-infective options for children and adolescents
  • Discuss the implementation of long-acting antiretroviral therapies in resource-limited settings

Is This Program for You?

This module is designed for clinicians, researchers, program managers, and public health professionals involved in HIV prevention and treatment. It is particularly relevant for those focused on pediatric and adolescent care, as well as those working in resource-limited environments where innovative therapeutic options are critical.

What Will You Cover in This Module?

  • Current and Future Perspectives in HIV Prevention
  • The Long-Acting Anti-Infective Agents for Children and Adolescents
  • Long-Acting Anti-Infectives in Resource-Limited Settings